• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

作者信息

Wang Zhijie, Wu Lin, Li Baolan, Cheng Ying, Li Xiaoling, Wang Xicheng, Han Liang, Wu Xiaohong, Fan Yun, Yu Yan, Lv Dongqing, Shi Jianhua, Huang Jianjin, Zhou Shaozhang, Han Baohui, Sun Guogui, Guo Qisen, Ji Youxin, Zhu Xiaoli, Hu Sheng, Zhang Wei, Wang Qiming, Jia Yuming, Wang Ziping, Song Yong, Wu Jingxun, Shi Meiqi, Li Xingya, Han Zhigang, Liu Yenpeng, Yu Zhuang, Liu An-Wen, Wang Xiuwen, Zhou Caicun, Zhong Diansheng, Miao Liyun, Zhang Zhihong, Zhao Hui, Yang Jun, Wang Dong, Wang Yingyi, Li Qiang, Zhang Xiaodong, Ji Mei, Yang Zhenzhou, Cui Jiuwei, Gao Beili, Wang Buhai, Liu Hu, Nie Lei, He Mei, Jin Shi, Gu Wei, Shu Yongqian, Zhou Tong, Feng Jian, Yang Xinmei, Huang Cheng, Zhu Bo, Yao Yu, Tang Xiongwen, Yu Jianjun, Maher Ellen, Feng Hui, Yao Sheng, Keegan Patricia, Wang Jie

机构信息

CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

出版信息

Future Oncol. 2025 Feb;21(5):515-522. doi: 10.1080/14796694.2024.2426951. Epub 2024 Dec 4.

DOI:10.1080/14796694.2024.2426951
PMID:39628302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11845098/
Abstract
摘要

相似文献

1
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).托瑞帕利单抗联合化疗治疗晚期非小细胞肺癌（NSCLC）的CHOICE-01试验结果的通俗语言总结。
Future Oncol. 2025 Feb;21(5):515-522. doi: 10.1080/14796694.2024.2426951. Epub 2024 Dec 4.
2
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.托瑞帕利单抗联合化疗治疗转移性或复发性三阴性乳腺癌的TORCHLIGHT试验结果的通俗语言总结。
Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4.
3
Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.从中国视角看，替雷利珠单抗联合化疗作为无EGFR或ALK驱动基因突变的晚期非小细胞肺癌（NSCLC）患者一线治疗的成本效益分析
Front Pharmacol. 2023 May 17;14:1133085. doi: 10.3389/fphar.2023.1133085. eCollection 2023.
4
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).特瑞普利单抗联合化疗用于未经治疗的晚期非小细胞肺癌患者的多中心随机 III 期临床试验（CHOICE-01）。
J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7.
5
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).诱导性 PD-1 抑制剂特瑞普利单抗联合化疗，随后行同期放化疗和巩固性特瑞普利单抗治疗局部晚期非小细胞肺癌的容积肿瘤患者：一项随机 II 期试验方案（InTRist 研究）。
Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023.
6
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.可切除非小细胞肺癌患者围手术期替雷利珠单抗联合化疗：Neotorch 随机临床试验。
JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735.
7
Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.特瑞普利单抗联合化疗对比单纯化疗用于中国晚期非小细胞肺癌的成本效果分析。
Front Immunol. 2023 May 29;14:1169752. doi: 10.3389/fimmu.2023.1169752. eCollection 2023.
8
Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.特瑞普利单抗联合化疗治疗非小细胞肺癌的经济学评价。
Front Public Health. 2023 Mar 24;11:1137255. doi: 10.3389/fpubh.2023.1137255. eCollection 2023.
9
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.帕博利珠单抗与新型 PD-1 抑制剂特瑞普利单抗用于局部晚期或转移性非鳞状非小细胞肺癌的成本效益和预算中性扩展准入模型研究。
J Med Econ. 2024;27(sup3):24-33. doi: 10.1080/13696998.2024.2380872. Epub 2024 Aug 1.
10
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.FLAURA2研究结果的通俗易懂总结：初始（一线）奥希替尼联合化疗对EGFR突变的晚期非小细胞肺癌患者大脑的影响。
Future Oncol. 2025 Apr;21(8):917-928. doi: 10.1080/14796694.2025.2463318. Epub 2025 Mar 6.